<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939039</url>
  </required_header>
  <id_info>
    <org_study_id>GENELIP</org_study_id>
    <nct_id>NCT03939039</nct_id>
  </id_info>
  <brief_title>From Known to New Genes in Dyslipidemia</brief_title>
  <acronym>GENELIP</acronym>
  <official_title>Genetical Characterization of Patients Presenting With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mechanism of the majority of the dyslipidemia is multifactorial at the molecular level
      and remains elusive in more than 50% of the patients in many clinical conditions. Next
      generation sequencing, a booming strategy, improves the molecular diagnosis efficiency in
      both monogenic and polygenic dyslipidemia.

      In order to decipher the mechanisms involved in the occurrence of dyslipidemia, in addition
      to the exploration of known candidate genes and Single Nucleotide Polymorphisms (SNP)
      involved in polygenic modulation, new genes involved in the regulation of lipoprotein
      metabolism or associated with lipids concentrations need to be sequenced in large groups of
      dyslipidemic patients.

      The goal of this project is to gain new insight into genotype/phenotype correlation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2000</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetical exploration in dyslipidemic patients</measure>
    <time_frame>25 years</time_frame>
    <description>Deoxyribonucleic Acid (DNA) sequencing will allow the study of rare gene variants and their frequency in known and new genes in patients with dyslipidemia.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Dyslipidemia</arm_group_label>
    <description>Genotype/phenotype correlation in patients with dyslipidemia</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Deoxyribonucleic Acid (DNA) of patients will sequenced using Sanger and Illumina
      Next-Generation Sequencing (NGS) methodology combined with PapilLyon, the pipeline developed
      by the Hospices Civils de Lyon (HCL) bioinformatics team, which allows more than 350 genes
      potentially involved in plasma lipoprotein metabolism to be explored.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients with dyslipidemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a family documented history of primary hypercholesterolemia,
             hypertriglyceridemia, hypobetalipoproteinemia, combined hypolipidemia and combined
             hyperlipidemia according to the European Atherosclerosis Society and/or published
             data.

          -  patients with major secondary dyslipidemia.

        Exclusion Criteria:

          -  inability to provide written informed consent

          -  lack of legal representative
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Moulin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathilde Di Filippo</last_name>
    <phone>4 72 11 89 94</phone>
    <phone_ext>33</phone_ext>
    <email>mathilde.di-filippo@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oriane Marmontel</last_name>
    <phone>4 72 12 97 08</phone>
    <phone_ext>33</phone_ext>
    <email>oriane.marmontel@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratoire de Biologie Médicale Multi Sites, Centre de Biologie et de Pathologie Est, Département de biochimie et biologie moléculaire Grand Est</name>
      <address>
        <city>Bron</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Di Filippo</last_name>
      <phone>4 72 11 89 94</phone>
      <phone_ext>33</phone_ext>
      <email>mathilde.di-filippo@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

